PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Negative cost of revenue growth (cost reduction) can be positive but verify quality impact. Benjamin Graham would examine if cost cuts are sustainable.
4.31%
Gross profit growth below 5% signals weak core performance. Seth Klarman would demand evidence of turnaround potential.
No Data
No Data available this quarter, please select a different quarter.
4.88%
R&D growth 0-5% reflects moderate investment. Benjamin Graham would check if spending drives future value.
-40.17%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-8.25%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
8.31%
EBITDA growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
8.25%
Operating income growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
133.19%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
12.55%
Pre-tax income growth 12-15% shows strong earnings momentum. Peter Lynch would examine growth drivers.
No Data
No Data available this quarter, please select a different quarter.
175.66%
Tax expense growth above 20% signals concerning expansion. Seth Klarman would scrutinize tax strategy.
12.55%
Net income growth 12-15% shows strong earnings momentum. Peter Lynch would examine growth drivers.
No Data
No Data available this quarter, please select a different quarter.
15.52%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
15.52%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
3.21%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
3.21%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.